Partnership / Collaboration · Latin America · Announced 9 Nov 2026
Bristol Myers Squibb → A.C.Camargo Cancer Center
Bristol Myers Squibb and Brazil's A.C.Camargo Cancer Center signed BMS's first oncology shared-risk agreement in Brazil, tying payment for nivolumab plus ipilimumab in first-line lung cancer to clinical outcomes.
Parties: Bristol Myers Squibb (BMS Brasil) (United States) → A.C.Camargo Cancer Center (Brazil)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- Brazil
- Therapeutic area
- Oncology
- Assets
- nivolumab; ipilimumab
- Announced
- 9 Nov 2026
Our analysis
Why this matters
Bristol Myers Squibb's Brazilian affiliate and A.C.Camargo Cancer Center announced on 9 November 2026 a shared-risk agreement for the combination of nivolumab and ipilimumab in first-line non-small cell lung cancer. It is described as BMS's first oncology shared-risk agreement in Brazil. Both drugs are already approved by Anvisa and commercially available. Financial terms and duration were not disclosed; the parties describe it as a long-term alliance.
Outcome-based contracts remain rare in Latin American oncology, where private payers and hospitals carry much of the cost of high-priced immunotherapies. For market-access and commercial leaders, the deal is a working template for sharing clinical risk with a provider rather than discounting list prices.
The full analysis is free to read with a work email on this page.
Source: Saúde Digital News